News | May 18, 2021
Outlook promising for Cipla: HDFC Securities
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Subscribe To Our Newsletter & Stay Updated
